Interim Report – January to September 2010

Non-Regulatory

October 26, 2010

Financial Highlights

• Revenue for the first nine months of 2010 was SEK 20.3 (19.0)million
• Net loss for the period amounted to SEK -15.8 (-19.0) million
• Earnings per share was SEK -0.19 (-0.42)
• Cash flow from current operations was SEK -18.5 (-31.4) million
• SEK 27.6m raised in additional financing of which 23.8m in cash

Key Corporate Highlights

• Shortly after the close of the reporting period Affibody and Amylin entered into a license agreement regarding the Albumod™ platform.
• During the period Affibody signed an agreement with an undisclosed company regarding its HER2 molecular imaging program, which includes ABY-025.
• The Swedish Governmental Agency for Innovation Systems (VINNOVA) has awarded Affibody a grant from their Innovations for Future Health program. The grant will enable Affibody to take the Albumod™ technology to human clinical testing.
• The Swedish MPA (Läkemedelsverket) has approved an exploratory clinical study in breast cancer patients at Uppsala University Hospital, Uppsala, Sweden with Affibody’s lead molecular imaging agent, ABY-025.
• The share issue directed to existing shareholders raised SEK 27.6 million gross to the company after which the total number of shares increased to 102 858 403.

David Bejker CEO, said: “We are pleased to announce our agreement with Amylin. It is encouraging that our focused research and business development activities have started to pay off. Our platforms continue to generate significant interest both from industry and academia. ”